Neurology Alert – August 1, 2016
August 1, 2016
View Issues
-
Guillain-Barré Syndrome in the Elderly
Guillain-Barré syndrome in the very old (> 80 years of age) results in more severe disease with poorer recovery.
-
For Migraine Pain, Green Light May Give Relief
Migraine-related photophobia appears to originate in cone-driven retinal pathways and is then mediated by thalamic neurons. Green light causes less stimulation than other colors.
-
What is the End Game in Creutzfeldt-Jakob Disease Progression?
Cerebellar and psychiatric symptoms at diagnosis of Creutzfeldt-Jakob disease may portend a higher risk for more rapid development of akinetic mutism.
-
Structural and Functional Imaging ‘Phenotypes’ in Refractory Temporal Lobe Epilepsy Patients
Using high-resolution 3-T magnetic resonance imaging, temporal lobe epilepsy-hippocampal sclerosis showed significant preoperative ipsilateral volume loss, T2 hyperintensity, and mean diffusivity increases across all subfields, with the greatest effects seen anteriorly. However, temporal lobe epilepsy-gliosis showed increased volume in the dentate gyrus bilaterally, and more focal and subtle increases in T2 intensity and mean diffusivity.
-
Stiff-Person Spectrum Disorder: What Can Antibody Profiles Tell Us?
This retrospective study of 121 patients with stiff-person spectrum disorder extensively examined antibody correlates of clinical features. Anti-GAD65 antibodies were highly associated with typical stiff-person syndrome, and anti-GlyR antibodies with SPS-plus. However, presence of anti-GAD antibodies predicted worse outcome than presence of antiGlyR antibodies, independent of clinical subtype.
-
In Patients with Intracerebral Hemorrhage, Intensive Lowering of Blood Pressure Does Not Improve Outcome
intensive treatment of patients with intracerebral hemorrhage to achieve a target systolic blood pressure < 120 mmHg did not result in a lower rate of death or disability, but did result in an increased rate of renal adverse events.
-
Ticagrelor vs. Aspirin for Secondary Stroke Prevention — About the Same!
Ticagrelor was not found to be superior to aspirin in reducing the rate of stroke, myocardial infarction, or death within 90 days, but there was a trend toward a reduced rate of ischemic stroke, that did not reach statistical significance.